Evidence map›Paper›PMID 30140377›Full record

ArticleOncotarget2018

Optical

Giulia Marelli, Roberta Avigni, Paola Allavena, Cecilia Garlanda, Alberto Mantovani, Andrea Doni, Marco Erreni

Open access · diamondAbstract read
In one paragraph

Article in Oncotarget, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.5field-weighted citation impact, top 37% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 5 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 2 countries.

Giulia MarelliIRCCS Humanitas Clinical and Research Center, Rozzano, Milan, Italy.
Roberta AvigniIRCCS Humanitas Clinical and Research Center, Rozzano, Milan, Italy.
Paola AllavenaIRCCS Humanitas Clinical and Research Center, Rozzano, Milan, Italy.
Cecilia GarlandaIRCCS Humanitas Clinical and Research Center, Rozzano, Milan, Italy.
Alberto MantovaniIRCCS Humanitas Clinical and Research Center, Rozzano, Milan, Italy.
Andrea DoniIRCCS Humanitas Clinical and Research Center, Rozzano, Milan, Italy.
Marco ErreniIRCCS Humanitas Clinical and Research Center, Rozzano, Milan, Italy.
Humanitas University · ITIstituti di Ricovero e Cura a Carattere Scientifico · ITQueen Mary University of London · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Optical imaging and Fluorescent Molecular Tomography (FMT) are becoming increasingly important for the study of different preclinical models of cancer, providing a non-invasive method for the evaluation of tumor progression in a relatively simple and fast way. Intestinal tumors, in particular colorectal cancer (CRC), represent a major cause of cancer-related death in Western countries: despite the presence of a number of preclinical models of intestinal carcinogenesis, there is a paucity of information about the possibility to detect intestinal tumors using fluorescent probes and optical

Indexed as

FMTintegrin αVβ3, colorectal cancerintestine tumoroptical imaging

Identifiers

PMID30140377
PMCPMC6101137
OpenAlexW2887367511

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.